Published 11 June 2026 · DaXem GmbH editorial · Reading time ~6 minutes · Based on Almeida-Pinto, Pinto & Rocha (2024), Infectious Diseases and Therapy
What the study examined
The review, titled “Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches,” was published in January 2024 by Francisca Almeida-Pinto, Rui Pinto and João Rocha of the Faculty of Pharmacy, University of Lisbon. It walks through the biology of the Ebola virus (EBOV) — a member of the Orthoebolavirus genus within the Filoviridae family — and connects that biology to how current and emerging therapeutics actually work.
Since Ebola first emerged in 1976, the world has faced a series of outbreaks, with the 2013–2016 West African epidemic marking a turning point in global awareness. The authors argue that understanding the virus’s replication cycle is the foundation for designing effective antiviral strategies.
Why Ebola is so hard to treat
Ebola virus carries a non-segmented, negative single-stranded RNA genome made up of seven genes that encode multiple proteins. The review stresses a crucial point: these proteins cannot be treated as single-function units. Instead, they work together — often multifunctionally — to infect host cells and drive the virus’s pathogenicity. That interconnected design is exactly what makes the virus difficult to target, because blocking one protein rarely stops the whole machine.
The two approved antibody therapies
As of the review, Ebola treatment two antibody-based therapeutics have received regulatory approval for Zaire ebolavirus, both targeting the viral glycoprotein the virus uses to enter human cells:
| Therapy | Type | Notes from the evidence base |
|---|---|---|
| Inmazeb (atoltivimab / maftivimab / odesivimab) | Three-antibody combination | First treatment approved for EVD; targets the Ebola glycoprotein. |
| Ebanga (ansuvimab, mAb114) | Single monoclonal antibody | Derived from a 1995 Kikwit outbreak survivor; targets the same glycoprotein. |
Both were evaluated in the WHO-coordinated PALM trial (“Pamoja Tulinde Maisha”) during the 2018–2020 outbreak in the Democratic Republic of the Congo. In that trial, the monoclonal-antibody therapies outperformed earlier candidates such as ZMapp and the antiviral remdesivir, and survival was substantially higher among patients treated early, when viral loads were still low. In 2022, the first evidence-based clinical practice guideline dedicated to EVD-specific therapies was published — a milestone the review highlights.
Emerging approaches: three strategic routes
The review organises the next generation of Ebola therapeutics into three broad strategies, each with trade-offs:
1. Direct-acting antivirals
These target viral proteins directly. The advantage is specificity; the challenge is that the virus can mutate and that its proteins are deeply interdependent.
2. Host-directed antivirals
Rather than the virus, these target the host factors the virus depends on to replicate. This can raise the barrier to resistance, but it requires careful management of effects on the patient’s own cells.
3. Drug repurposing
One pragmatic way to bypass long development timelines is to repurpose drugs already approved for other indications. Because their safety profiles are known, repurposed candidates can move toward EVD use faster than entirely new molecules.
The prevention dimension the headlines often miss
The review’s central message is sobering: even with notable progress, deaths from Ebola still occur, and there is an urgent need to improve outcomes. That reality is a reminder that treatment is only one half of outbreak response. The other half is stopping transmission in the first place — through case isolation, safe care practices, personal protective equipment, hand hygiene, and the decontamination of contaminated environments and surfaces.
High-consequence pathogens spread, in part, through contact with contaminated surfaces and equipment in clinical and community settings. That is why environmental hygiene sits alongside therapeutics in every serious infection-prevention framework. Disinfection events reduce surface contamination at a single point in time — but surfaces can be re-contaminated within minutes of cleaning through touch, traffic and aerosol settlement.
Where continuous antimicrobial surface protection fits
This is the gap that supplemental residual antimicrobial technology is designed to address. VireXbuster is a hybrid antimicrobial coating with a very wide spectrum of activity against viruses, bacteria, fungi, mould and mildew. Critically, it is not a medicine and not a disinfectant — it is a supplemental, residual layer that keeps working on treated surfaces in the hours and days between cleaning and disinfection, helping to suppress microbial re-growth on the surface itself.
To be clear and accurate: VireXbuster has not been tested against filoviruses such as Ebola and makes no claim of efficacy against them. The relevance of this research to our work is broader — it underlines why layered, continuous environmental hygiene deserves a permanent place in modern infection-prevention strategy, in hospitals, public buildings, transport, hospitality and beyond.
VireXbuster is independently validated as an antimicrobial: BAuA-notified, Fraunhofer-tested, QualityLabs-certified as antimicrobial, and Dermatest-certified as dermatologically safe (“Excellent”). The product family includes:
- VireXbuster Spray — a ready-to-use antimicrobial coating for hard surfaces (1 L, €92.48).
- VireXbuster Wall — a waterborne antimicrobial wall paint for walls and ceilings (5 L, €126.54).
- VireXbuster 4Bulk — an additive for polymers and plastics manufacturing, including antimicrobial polymer floors.
Explore the range at the VireXbuster online shop, or
contact our team for facility-scale advice.
Frequently asked questions
Is there an approved treatment for Ebola virus disease?
Yes. Two antibody-based therapeutics are approved for Zaire ebolavirus: Inmazeb, a three-antibody combination, and Ebanga, a single monoclonal antibody. Both target the Ebola glycoprotein and improved survival in the WHO-coordinated PALM trial.
What are the emerging pharmacological approaches to Ebola in 2024?
The review groups them into three routes: direct-acting antivirals that target viral proteins, host-directed antivirals that target host factors the virus depends on, and the repurposing of already-approved drugs to shorten development time.
Why is Ebola so difficult to treat?
Its seven-gene, negative single-stranded RNA genome encodes proteins that act together, often multifunctionally, to infect host cells. Because no single protein works in isolation, designing targeted antivirals is unusually complex.
How does infection prevention fit into Ebola outbreak response?
Treatment helps people who are already infected, but outbreak control also depends on stopping transmission — through isolation, protective equipment, hand hygiene and environmental decontamination of surfaces, working alongside therapeutics.
Is VireXbuster a treatment or disinfectant for Ebola?
No. VireXbuster is neither a medicine nor a disinfectant. It is a supplemental residual antimicrobial surface coating that provides continuous protection on treated surfaces between disinfection events. It has not been tested against filoviruses such as Ebola and makes no claim against them.
Source
Almeida-Pinto F, Pinto R, Rocha J. Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches. Infectious Diseases and Therapy. 2024 Jan;13(1):21–55. PMID: 38240994. DOI: 10.1007/s40121-023-00913-y. Open access (CC BY-NC). View on PubMed.
Entities referenced: Ebola virus disease · Filoviridae · Orthoebolavirus · Inmazeb · Ebanga · monoclonal antibody · PALM trial · World Health Organization · infection prevention and control · VireXbuster · DaXem GmbH.
Disclaimer: This article summarises published scientific research for general information and does not constitute medical advice. VireXbuster is a supplemental residual antimicrobial product, not a disinfectant and not a therapeutic; it is intended to complement — never replace — cleaning, disinfection and established infection-control protocols. No claim is made regarding efficacy against Ebola virus or other filoviruses.
